Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells
Abstract Marine sponges and their associated microbiota are multicellular animals known to produce metabolites with interesting pharmacological properties playing a pivotal role against a plethora of pathologic disorders such as inflammation, cancer and infections. Characellide A and B belong to a novel class of glycolipopeptides isolated from the deep sea marine sponge Characella pachastrelloides. In this study, we have evaluated the effects of characellide A and B on cytokine and chemokine release from human peripheral blood mononuclear cells (PBMC). Characellide A induces a concentration- and time-dependent CXCL8, IL-6 and TNF-α release from PBMC. This production is mediated by the induction of gene transcription. Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically inhibits characellide A-induced activation of PBMC. In conclusion, characellide A is a novel modulator of adaptative/innate immune responses. Further studies are needed to understand its potential pharmacological application..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Inflammopharmacology - 29(2021), 4 vom: 09. Juli, Seite 1201-1210 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Marcella, Simone [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s10787-021-00836-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2126786854 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2126786854 | ||
003 | DE-627 | ||
005 | 20230505121415.0 | ||
007 | tu | ||
008 | 230505s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s10787-021-00836-5 |2 doi | |
035 | |a (DE-627)OLC2126786854 | ||
035 | |a (DE-He213)s10787-021-00836-5-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Marcella, Simone |e verfasserin |4 aut | |
245 | 1 | 0 | |a Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Abstract Marine sponges and their associated microbiota are multicellular animals known to produce metabolites with interesting pharmacological properties playing a pivotal role against a plethora of pathologic disorders such as inflammation, cancer and infections. Characellide A and B belong to a novel class of glycolipopeptides isolated from the deep sea marine sponge Characella pachastrelloides. In this study, we have evaluated the effects of characellide A and B on cytokine and chemokine release from human peripheral blood mononuclear cells (PBMC). Characellide A induces a concentration- and time-dependent CXCL8, IL-6 and TNF-α release from PBMC. This production is mediated by the induction of gene transcription. Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically inhibits characellide A-induced activation of PBMC. In conclusion, characellide A is a novel modulator of adaptative/innate immune responses. Further studies are needed to understand its potential pharmacological application. | ||
650 | 4 | |a IL-6 | |
650 | 4 | |a TNF-α | |
650 | 4 | |a Simplexide | |
650 | 4 | |a CD1d | |
650 | 4 | |a LPS | |
700 | 1 | |a Afoullouss, Sam |4 aut | |
700 | 1 | |a Thomas, Olivier P. |4 aut | |
700 | 1 | |a Allcock, A. Louise |4 aut | |
700 | 1 | |a Murphy, Paul V. |4 aut | |
700 | 1 | |a Loffredo, Stefania |0 (orcid)0000-0002-5871-1898 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Springer International Publishing, 1991 |g 29(2021), 4 vom: 09. Juli, Seite 1201-1210 |w (DE-627)170602893 |w (DE-600)1080058-X |w (DE-576)505034115 |x 0925-4692 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2021 |g number:4 |g day:09 |g month:07 |g pages:1201-1210 |
856 | 4 | 1 | |u https://doi.org/10.1007/s10787-021-00836-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_4277 | ||
936 | b | k | |a 44.00 |q VZ |
951 | |a AR | ||
952 | |d 29 |j 2021 |e 4 |b 09 |c 07 |h 1201-1210 |